^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners

    TEST:
    OncoSeek®

    Company:
    SeekIn
    Type:
    CE Marked
    Related tests:
    Details
    Evidence

    News

    2ms
    OncoInv partners with Healthcare Systems Mexico to bring multi-cancer early detection to Mexico (SeekIn Press Release)
    "OncoInv and Healthcare Systems Mexico have joined forces to make multi cancer early detection available in Mexico. Healthcare Systems Mexico will be an exclusive distributor for OncoInv and will offer OncoSeek® as a novel means of detection of cancer in Mexico. OncoSeek® is a patient-friendly product to detect nine forms of cancer simultaneously based on a blood sample and requires no biopsy or imaging equipment."
    Licensing / partnership
    |
    OncoSeek®
    4ms
    SeekIn secures eight EU trademark authorizations, expanding its cancer detection technology portfolio (SeekIn Press Release)
    "SeekIn Inc...announced today that it has obtained authorization to use eight trademarks within the European Union, including SeekInCare (the first-in-class blood-based pan-cancer early detection test), SeekInCure (the first-in-class blood-based pan-cancer recurrence monitoring test), SeekInClarity (pan-cancer treatment response monitoring), OncoSeek (low-cost early cancer detection test), LungCanSeek (lung cancer early detection test), LeukoPrint (the first-in-class leukemia sWGS CNA test), PanCanSeek (pan-cancer therapy guidance test)..."
    Regulatory
    |
    LeukoPrint® • OncoSeek® • PanCanSeek® • SeekInCare™ • SeekInClarity® • SeekInCure®
    9ms
    SeekIn Presents New OncoSeek Data at the AACR Annual Meeting in San Diego (PRNewswire)
    "SeekIn Inc., a leader in blood-based cancer early detection and monitoring technology, today announced three additional validation studies that evaluate OncoSeek's ability to detect more than nine cancer types and predict the tissue of origin with a tube of blood. The data further validate the performance of OncoSeek with consistent results between the three new cohorts and the three previous cohorts of ~12,000 participants from China, the United States and Brazil. The results from three different platforms and two sample types indicate the generalization of OncoSeek's capability for common protein marker platforms."
    Clinical
    |
    OncoSeek®
    10ms
    Phenotypic and genotypic characterization of single circulating tumor cells in the follow-up of high-grade serous ovarian cancer (AACR 2024)
    We combined immunomagnetic enrichment and image-based sCTC sorting for phenotypic and genotypic analysis of sCTCs in the follow-up of OC to provide insights into sCTC heterogeneity and their malignant character.Patients and 10 ml blood of high-grade serous OC patients (pts) at the time of primary diagnosis (n=42), after chemotherapy (n=23) and after Avastin (n=11) was analyzed for sCTCs using density-gradient centrifugation to further apply MACS® using CD45 and CD235a antibodies coupled to MACS® MicroBeads... We identified sCTCs in the follow-up of OC and demonstrated interpatient as well as intrapatient heterogeneity of sCTCs. Matched sCTCs and PT data showed similar CNAs to a certain amount. Our low percentage of aberrant cells suggests that higher patient numbers are needed to confirm our findings to understand disease progression.
    Circulating tumor cells • Tumor cell
    |
    ALK (Anaplastic lymphoma kinase) • TP53 (Tumor protein P53) • FOLR1 ( Folate receptor alpha ) • CDK4 (Cyclin-dependent kinase 4) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • VIM (Vimentin)
    |
    OncoSeek®
    |
    Avastin (bevacizumab)
    10ms
    Large-scale validaton studies of a blood-based effective and affordable test for multicancer early detection (AACR 2024)
    Moreover, the accuracy of TOO facilitates the follow-up diagnostic workup. OncoSeek is affordable (~$20) and accessible requiring nothing more than a blood draw at the screening sites, which makes it adoptable in LMICs.
    MUC16 (Mucin 16, Cell Surface Associated) • CA 19-9 (Cancer antigen 19-9)
    |
    OncoSeek®
    1year
    SeekIn and OncoInv Collaborate to Expand the Global Accessibility of Multiple Cancer Detection Tests and Bridge Global Disparities in Cancer Care (PRNewswire)
    "SeekIn Inc...announced a strategic collaboration with Oncolnv, a fully-owned affiliate of Inspire2Live, to expand the global accessibility of their multiple cancer detection tests and bridge disparities in cancer care. Starting this December, SeekIn's comprehensive range of cancer detection tests, namely OncoSeek, SeekInCare, SeekInCure and SeekInClarity will be distributed by Oncolnv in the following twelve countries: Belgium, Bulgaria, Costa Rica, Egypt, Ghana, Kenya, the Netherlands, Nigeria, Qatar, Singapore, Tanzania and UAE."
    Licensing / partnership
    |
    OncoSeek® • SeekInCare™ • SeekInClarity® • SeekInCure®
    1year
    SeekIn presents new validation studies of OncoSeek multi-cancer early detection test at Early Detection of Cancer Conference in London (SeekIn Press Release)
    "SeekIn Inc...announced two additional validation studies that evaluate OncoSeek's ability to detect more than nine cancer types and predict the tissue of origin with a tube of blood. The data further validate the performance of OncoSeek with the consistent results between the two new cohorts and the three previous cohorts of ~10,000 participants from China and the United States."
    Clinical data
    |
    OncoSeek®
    over1year
    SeekIn's CEO highlights revolutionary multi-cancer early detection technology at BIOHK2023 (SeekIn Press Release)
    "SeekIn Inc...announces the participation of Dr. Mao, CEO and Co-founder, in the highly anticipated BIOHK2023 conference. The CEO took the stage to deliver an engaging presentation, shedding light on the technological roadmap, exceptional performance, and extensive applications of their groundbreaking multi-cancer early detection product, called OncoSeek."
    Clinical data
    |
    OncoSeek®
    over1year
    A panel of seven protein tumour markers for effective and affordable multi-cancer early detection by artificial intelligence: a large-scale and multicentre case-control study. (PubMed, EClinicalMedicine)
    Moreover, the accuracy of TOO facilitates the follow-up diagnostic workup. The National Key Research and Development Programme of China.
    Journal
    |
    OncoSeek®
    over1year
    SeekIn paves the way for cancer early detection in low- and middle-income countries (PRNewswire)
    "SeekIn Inc...announced that a research article titled 'A panel of seven protein tumor markers for effective and affordable multicancer early detection by artificial intelligence' has been published in eClinicalMedicine, a clinical journal published by The Lancet. This is a major breakthrough for SeekIn's multi-cancer early detection (MCED) tests in the oncology field, and a high recognition of SeekIn's technical strength and research & development capabilities."
    Retrospective data • Observational data
    |
    OncoSeek®
    over1year
    A panel of seven protein tumor markers for multi-cancer early detection by artificial intelligence. (ASCO 2023)
    In summary, this study supported that OncoSeek significantly outperforms the conventional clinical method, representing a novel blood-based test for multi-cancer early detection which is a non-invasive, easier, and efficient approach. Moreover, the accuracy of TOO of it which facilitates the follow-up diagnostic workup. As well as this method is affordable (the cost of the test is less than $25) and requires nothing more than a blood draw at the screening sites, which makes it more practical in low- and middle-income countries.
    OncoSeek®
    almost2years
    Next-Generation Sequencing Identifies Approximately One Third of Mantle Cell Lymphoma Patients with Nuclear Factor-kappa B Pathway Mutations (USCAP 2023)
    Approximately one third of de novo MCL cases harbor mutations in genes involving the NF-κB pathway. TP53 mutation was significantly infrequent in these patients compared with patients without NF-κB pathway mutations, suggesting a different molecular pathogenesis. This subset of MCL patients could be candidates for therapeutic agents targeting the NF-κB pathway.
    Clinical • Next-generation sequencing
    |
    TP53 (Tumor protein P53) • NOTCH1 (Notch 1) • MYD88 (MYD88 Innate Immune Signal Transduction Adaptor) • CCND1 (Cyclin D1) • KMT2D (Lysine Methyltransferase 2D) • SMARCA4 (SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily A, member 4) • NOTCH2 (Notch 2) • BIRC3 (Baculoviral IAP repeat containing 3) • CARD11 (Caspase Recruitment Domain Family Member 11) • IRF4 (Interferon regulatory factor 4) • NFKBIE (NFKB Inhibitor Epsilon) • NSD2 (Nuclear Receptor Binding SET Domain Protein 2) • TRAF6 (TNF Receptor Associated Factor 6) • UBR5 (Ubiquitin Protein Ligase E3 Component N-Recognin 5)
    |
    TP53 mutation • ATM mutation
    |
    OncoSeek®
    2years
    Mutation Spectrum, Characteristics and Impact of Mutation Profiling on Prognosis, Outcome and Treatment Responses in Patients (pts) with Mantle Cell Lymphoma (ASH 2022)
    "Twenty-three pts were treated with standard of care brexucabtagene autoleucel (CART)... The clinical NGS-based assay for MCL pts at our institution has proven to have prognostic significance. Resistant MCL pts exhibit a preponderance of mutations involving TP53, epigenetic modifier and chromatin regulator genes. Comprehensive risk stratification of pts early on and during therapy is very useful and improves patient care, helps design next generation clinical trials and improves our understanding of the biology of resistant MCL in the BTKi and CART era."
    Clinical
    |
    TP53 (Tumor protein P53) • ATM (ATM serine/threonine kinase) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • DNMT3A (DNA methyltransferase 1) • RB1 (RB Transcriptional Corepressor 1) • NOTCH1 (Notch 1) • MYD88 (MYD88 Innate Immune Signal Transduction Adaptor) • SF3B1 (Splicing Factor 3b Subunit 1) • CCND1 (Cyclin D1) • BTK (Bruton Tyrosine Kinase) • TET2 (Tet Methylcytosine Dioxygenase 2) • KMT2D (Lysine Methyltransferase 2D) • SMARCA4 (SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily A, member 4) • CD79B (CD79b Molecule) • NOTCH2 (Notch 2) • BIRC3 (Baculoviral IAP repeat containing 3) • PAX5 (Paired Box 5) • CARD11 (Caspase Recruitment Domain Family Member 11) • NFKB1 (Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1) • IGLL5 (Immunoglobulin Lambda Like Polypeptide 5) • MAP3K14 (Mitogen-Activated Protein Kinase Kinase Kinase 14) • NSD2 (Nuclear Receptor Binding SET Domain Protein 2) • S1PR1 (Sphingosine-1-Phosphate Receptor 1) • UBR5 (Ubiquitin Protein Ligase E3 Component N-Recognin 5)
    |
    TP53 mutation • ATM mutation • SMARCA4 mutation • BTK mutation • BTK C481R • BTK C481Y • BTK T474I
    |
    OncoSeek®
    |
    Tecartus (brexucabtagene autoleucel)
    over2years
    SeekIn receives CE Mark approval for OncoSeek® Multi-Cancer Detection Test (PRNewswire)
    "SeekIn Inc...announced CE (Conformité Européenne) Mark approval for OncoSeek® Multi-Cancer Detection Test and is now ready to launch this test in European Union and other countries that recognize CE mark...OncoSeek®, a customized panel of seven selected protein tumor markers (PTMs) including AFP, CA125, CA15-3, CA19-9, CA72-4, CEA, and CYFRA21-1, quantified them on Roche cobas e411 instrument performing for 12 common cancers early detection."
    Launch Europe • European regulatory
    |
    OncoSeek®